Adolore Biotherapeutics, Inc. | WebDisclosure

Switch to English

10966	Sociétés
240147	Mots-clés
168916	Articles
129236	Communiqués

Accueil
Sociétés
Adolore Biotherapeutics, Inc.

COMMUNIQUÉ DE PRESSE

publié le 16/05/2024 à 16:00, il y a 2 années 3 mois

Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels
Adolore BioTherapeutics announces groundbreaking findings in gene therapy for chronic pain treatment, highlighting the value of non-opioid analgesics and progress with IND-enabling studies

Adolore BioTherapeutics Chronic Pain Gene Therapy Non-opioid Analgesics IND-enabling Studies
BRÈVE

publiée le 04/03/2024 à 16:05, il y a 2 années 6 mois

Adolore BioTherapeutics obtient un brevet américain pour la thérapie génique CA8* dans le traitement de la douleur chronique

Adolore BioTherapeutics Thérapie Génique Traitement De La Douleur Chronique Solutions Sans Opioïdes Délivrance De Brevet
BRÈVE

publiée le 04/03/2024 à 16:05, il y a 2 années 6 mois

Adolore BioTherapeutics Secures U.S. Patent for CA8* Gene Therapy in Chronic Pain Treatment

Adolore BioTherapeutics Gene Therapy Chronic Pain Treatment Opioid-Free Solutions Patent Issuance
COMMUNIQUÉ DE PRESSE

publié le 04/03/2024 à 16:00, il y a 2 années 6 mois

Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain
Adolore BioTherapeutics licenses patent and CA8* gene therapy technology from the University of Miami for opioid-free chronic pain treatment. Company progresses toward clinical testing and commercialization

University Of Miami Adolore BioTherapeutics Chronic Pain Opioid-free Gene Therapy
COMMUNIQUÉ DE PRESSE

publié le 30/01/2024 à 16:00, il y a 2 années 7 mois

Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting
Adolore BioTherapeutics will present at the 5th Annual NIH HEAL Initiative Scientific Meeting regarding the gene therapy program for chronic pain associated with knee osteoarthritis. The program is supported by NIH/NINDS HEAL UH3 Award

Adolore BioTherapeutics Chronic Pain NIH HEAL Initiative Gene Therapy Osteoarthritis
COMMUNIQUÉ DE PRESSE

publié le 05/12/2023 à 16:30, il y a 2 années 9 mois

Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain
Adolore BioTherapeutics presented preclinical data supporting its innovative CA8* gene therapy as a long-acting local analgesic for chronic osteoarthritis knee pain management, aiming to replace opioids

Adolore BioTherapeutics CA8* Gene Therapy Chronic Pain Opioid-free Preclinical Data
COMMUNIQUÉ DE PRESSE

publié le 11/10/2023 à 16:00, il y a 2 années 11 mois

Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference
COMMUNIQUÉ DE PRESSE

publié le 03/10/2023 à 15:15, il y a 2 années 11 mois

NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain

Les Echos

Publié le 11/09/2026 à 07:00, il y a 1 jour 13 heures

Transparantiekennisgeving van Baltisse Groep
Publié le 11/09/2026 à 07:00, il y a 1 jour 13 heures

Transparency notification by Baltisse Group
Publié le 11/09/2026 à 07:00, il y a 1 jour 13 heures

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Publié le 11/09/2026 à 07:00, il y a 1 jour 13 heures

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Publié le 10/09/2026 à 19:30, il y a 2 jours 1 heure

Availability of the 2026 Interim Financial Report

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 12/09/2026 à 02:35, il y a 18 heures 3 minutes

Gamma Resources Announces Extension of Private Placement Closing Date
Publié le 11/09/2026 à 23:00, il y a 21 heures 38 minutes

Rio Grande Resources Engages Machai Capital for Investor Outreach
Publié le 11/09/2026 à 22:05, il y a 22 heures 33 minutes

Usha Resources Announces Leadership Transition
Publié le 11/09/2026 à 21:25, il y a 23 heures 13 minutes

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Publié le 11/09/2026 à 17:00, il y a 1 jour 3 heures

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

Voir tout ACCESSWIRE

EQS Group

Publié le 12/09/2026 à 17:50, il y a 2 heures 48 minutes

New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Publié le 12/09/2026 à 07:30, il y a 13 heures 8 minutes

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Publié le 11/09/2026 à 22:15, il y a 22 heures 23 minutes

Amrize Appoints Mario Gross as President of Building Envelope
Publié le 11/09/2026 à 22:10, il y a 22 heures 28 minutes

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Publié le 11/09/2026 à 19:44, il y a 1 jour

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031